Ravulizumab
- Generic Name
- Ravulizumab
- Brand Names
- Ultomiris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1803171-55-2
- Unique Ingredient Identifier
- C3VX249T6L
- Background
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking terminal complem...
- Indication
Ravulizumab is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
...
- Associated Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Real-life Treatment Outcomes of Ravulizumab in PNH
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06633536
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06578949
- Locations
- 🇨🇳
Research Site, Wuhan, China
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT06398158
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 14
- Registration Number
- NCT06333652
- Locations
- 🇺🇸
Mayo Clinic Minnesota, Rochester, Minnesota, United States
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06291376
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05972967
- Locations
- 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 736
- Registration Number
- NCT05746559
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05644561
- Locations
- 🇨🇭
Research Site, Bern, Switzerland
Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05396742
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05346354
- Locations
- 🇪🇸
Research Site, Esplugues de Llobregat, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.